ArticleTurkish journal of medical sciences2026
Repurposing diclofenac for combination therapy: targeting the Warburg effect to enhance breast cancer treatment.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Diclofenac (Diclo), a widely used nonsteroidal antiinflammatory drug, has emerged as a potential candidate for drug repurposing in oncology, with reported anticancer effects extending beyond cyclooxygenase (COX) inhibition, including modulation of tumor metabolism. This study investigated the antiproliferative and glycolysis-associated effects of Diclo in MCF-7 breast cancer cells, alone and in combination with docetaxel (Doc) or 5-fluorouracil (5-FU). Materials and methods: Cell viability was assessed using the sulforhodamine B (SRB) assay. To evaluate metabolic alterations, glucose uptake and lactate release were quantified following treatment. In addition, Triosephosphate Isomerase (TPI) protein levels and Lactate Dehydrogenase (LDH) activity were measured to explore potential modulation of glycolytic pathways. Results: Diclo reduced MCF-7 viability in a dose-dependent manner (IC Conclusion: Diclo potentiated the cytotoxic effects of Doc and 5-FU and was associated with reduced glycolytic readouts and decreased TPI in MCF-7 cells, supporting a potential role for Diclo as a metabolic modulator in breast cancer combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.